Two SPAC’d biotechs raise additional money as Bihua Chen’s blank check closes $184M IPO
2024-02-14
IPO并购免疫疗法
The post-SPAC life isn’t all too great for most biotech companies — or those in other industries, for that matter. But some drug developers that went the blank-check route have found greener pastures in recent months, with two of them announcing large financings this week.
This is amid a second biotech SPAC from Bihua Chen, founder of Cormorant Asset Management. Known as Helix Acquisition Corp. II
$HLXB
, the SPAC closed a $184 million initial public offering on Wednesday. It will hunt for a biotech or other healthcare business to combine with after Helix I found success with MoonLake Immunotherapeutics.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
-靶点
-药物
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。